Author

K. Alfson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Research Focus:drug response / drug discovery· 2 Organism:non-human primate· 2 Organism:human· 1 Organism:mouse· 1 Organism:multiple species· 1 Assay:proteomics· 1

Frequent Co-Authors

R. Carrion· 5 shared H. M. Staples· 4 shared A. Cook· 3 shared A. Ahmed· 2 shared A. Anderson· 2 shared A. Baum· 2 shared A. Hajduczki· 2 shared A. J. Murphy· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

R. Carrion

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

H. A. D. King, M. G. Joyce, I. Elakhal Naouar, A. Ahmed, C. Macedo Cincotta, C. Subra, K. K. Peachman, H. H. Hack, R. E. Chen, P. V. Thomas, W.-H. Chen, R. S. Sankhala, A. Hajduczki, E. J. Martinez, C. E. Peterson, , L. L Jagodzinski

This study evaluates an adjuvanted SARS-CoV-2 RBD nanoparticle vaccine in macaques, showing robust immune responses and protection against viral challenge and variants.

bioRxiv · Apr 9, 2021Immunology

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

M. G. Joyce, H. A. D. King, I. Elakhal Naouar, A. Ahmed, K. K. Peachman, C. M. Cincotta, C. Subra, R. E. Chen, P. V. Thomas, W.-H. Chen, R. S. Sankhala, A. Hajduczki, E. J. Martinez, C. E. Peterson, W. C. Chang, , N. Karasavva

A SARS-CoV-2 Spike ferritin nanoparticle vaccine induces broad neutralizing antibodies and protects nonhuman primates against respiratory infection and disease.

bioRxiv · Mar 24, 2021 · PreprintImmunology

REGEN-COV protects against viral escape in preclinical and human studies

R. Copin, A. Baum, E. Wloga, K. E. Pascal, S. Giordano, B. O. Fulton, A. Zhou, N. Negron, K. Lanza, N. Chan, A. Coppola, J. Chiu, M. Ni, G. S. Atwal, A. Romero Hernandez, , C. A. Kyratsous

This study shows that REGEN-COV, a combination of non-competing antibodies, provides broad coverage against SARS-CoV-2 variants and prevents the emergence of new variants in clinical and preclinical settings.

bioRxiv · Mar 10, 2021 · PreprintMicrobiology

REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters

A. Baum, R. Copin, D. Ajithdoss, A. Zhou, K. Lanza, N. Negron, M. Ni, Y. Wei, G. S. Atwal, A. Oyejide, Y. Goez-Gazi, J. Dutton, E. Clemmons, H. M. Staples, C. Bartley, , C. A. Kyratsous

This study evaluates the efficacy of the REGN-COV2 antibody cocktail in preventing and treating SARS-CoV-2 infection in rhesus macaques and hamsters, showing reduced virus load and pathological effects.

bioRxiv · Aug 2, 2020Microbiology

Lethality of SARS-CoV-2 infection in K18 human angiotensin converting enzyme 2 transgenic mice

F. Oladunni, J.-G. Park, P. Pino Tamayo, O. Gonzalez, A. Ahkter, A. Allue Guardia, A. Olmo-Fontanez, S. Gautam, A. Garcia Vilanova, C. Ye, K. Chiem, C. Headley, V. Dwivedi, L. Parodi, K. Alfson, , J. B. Torrelles

This study demonstrates that K18 hACE2 transgenic mice are susceptible to SARS-CoV-2 infection, exhibit cytokine and chemokine storms, and serve as a model for studying viral pathogenesis and therapeutic development.

bioRxiv · Jul 18, 2020Microbiology